NCT05507736Completed
Feasibility and Safety of Acupuncture With Semi-Permanent Needles for the Prevention of Irinotecan-Associated Diarrhea in Pediatric Solid Tumors
Feasibility and Safety of Acupuncture With Semi-Permanent Needles for the Prevention of Irinotecan-Associated Diarrhea in Pediatric Solid Tumors: A Prospective Pilot Study
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
To evaluate the feasibility of an acupuncture protocol in the prevention of late diarrhea due to irinotecan in pediatric patients with solid tumors, a pre-post pilot study will be conducted. Pre-post pilot study non-randomized, open label, single arm study. There will be a single study group that will be used at the same time as your own control. The intervention will take place for approximately one year.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 6 Jul 2022
- Start date
- 1 Oct 2022
- Primary completion date
- 28 Feb 2023
- Lead sponsor
- Fundació Sant Joan de Déu
- Diseases
- Childhood cancers
- NCT number
- NCT05507736
What you commit to
- Study type: Interventional
- Participants enrolled: 22
- From 1 Oct 2022 to the primary completion date, 28 Feb 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received acupuncture treatment in the last ten days.
- Receive concomitant abdominal radiotherapy.
Other
- Participate in a clinical trial that is developed in the Pediatric Oncology Area of the Hospital Sant Joan de Deu where acupuncture intervention is not permitted.
- Have diarrhea on day 1 of the cycle
Who the study is looking for
- Patients from 0 to 18 years old with solid tumors who start treatment in our center with irinotecan at 50 mg/m2/intravenous dose in day hospital.
- Blood tests prior to the start of the appropriate chemotherapy cycle to receive acupuncture with continuous stimulation needle insertion: neutrophils greater or equal to 1000 cells/mm3 and platelets greater than or equal to 50,000 cells/mm3.
- Signature of informed consent by parents in the case of children under 12 years of age and assent of the minor.
- Signature of informed consent in the case of those over 12 years of age
Age in the registry: 0 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Sant Joan De Deu Coordinator of this site? Confirm its status | Esplugues de Llobregat | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.